Abstract
Coenzyme Q10 (CoQ10) is a naturally occurring compound that is found in animals and all humans. It has a fundamental role in cellular energy production. Although it is produced in the body, tissue deficiency can occur due to medications such as statins, which inhibit the mevalonate pathway. The clinical syndromes of statin-associated muscle symptoms (SAMS) and some of the features observed in patients with heart failure (HF) may be related to blood and tissue deficiency of CoQ10. Numerous clinical trials of CoQ10 in SAMS have yielded conflicting results. Yet, the weight of evidence as reflected in meta-analyses supports the use of exogenous CoQ10 in SAMS. In patients with HF, large-scale randomized clinical trials are lacking, although one relatively contemporary trial, Q-SYMBIO, suggests an adjunctive role for CoQ10. The possibility that statin-related CoQ10 deficiency may play a role in patients with diastolic HF is an intriguing hypothesis that warrants further exploration.
Original language | English (US) |
---|---|
Pages (from-to) | 609-619 |
Number of pages | 11 |
Journal | Journal of the American College of Cardiology |
Volume | 77 |
Issue number | 5 |
DOIs | |
State | Published - Feb 9 2021 |
Keywords
- CoQ
- coenzyme Q
- statin-associated cardiomyopathy
- statin-associated muscle symptoms
- Cardiovascular Diseases/prevention & control
- Humans
- Mitochondrial Diseases/drug therapy
- Muscle Weakness/drug therapy
- Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
- Ubiquinone/analogs & derivatives
- Ataxia/drug therapy
- Dietary Supplements
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine